Radient Pharmaceuticals Corporation fka RXPC

[primarywatcher]

Where new is OLD, and OLD is new...

Excerpt from Gold:
"Also, there is no indication that Gaur Diagno or Javia Technologies has any funding at all to develop CIT."

My thoughts exactly! Javia is nothing more than a marketing tool TO ADVANCE COMMERCIALIZATION of whatever the heck RPC claims to be pushing. Onko-Sure, CIT, ...you name it.

Below are documents reviewing Gold's statement:

On 09/10/2001:
AMDL Acquires Combination Immunogene Therapy Technology for the Eradication of Human Tumors
http://www.medica.de/cipp/md_medica/custom/pub/content,oid,1818/lang,2/ticket,g_u_e_s_t/mcat_id,7885/local_lang,2/~/AMDL_Acquires_Combination_Immunogene_Therapy_Technology_for_the_Eradication_of_Human_Tumors.html

After purchasing CIT from Dr. Chang, AMDL later obtained US Patent for "CIT" on May 25, 2004.
http://www.redorbit.com/news/health/1050160/otc_stock_review_and_amex_review_announce_coverage_of_amdl/index.html

Lawsuit was filed against AMDL on 2/22/2002; refer: P45, Pt.II, Item 1:
http://google.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHtmlSection1?SectionID=6254246-226673-230766&SessionID=zRoyHqfwJUKJbs7

Here is summary - it appears the case was dismissed voluntarily?
http://www.legalmetric.com/cases/patent/cacd/cacd_802cv00037.html#s27

From charts dating back to 2006, I tried to locate what happened in last quarter of 2007. Here is link to filings dating back to May 15, 1996 (refer pg. 45):
http://www.otcmarkets.com/stock/RPC/financials

Perhaps this explains the 2007 drop:
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=5555339

On November 13, 2007, the Company received a memorandum of “Review Issues” from the United States Food and Drug Administration (“US FDA”) which addresses the pending application for 510(k) approval of DR-70 ® as an aid in monitoring the disease status in patients who have been previously diagnosed with colorectal cancer. Unlike prior communications from the US FDA, the US FDA did not raise the issue of whether the Company’s test was substantially equivalent to the existing predicate test, CEA. The memorandum includes requests for clarification of the intended use statement and clinical outcome measures.

The US FDA requested a response to the comments within 30 days, but also indicated a request for more time could be made. The company is analyzing the comments and has not yet determined whether it can supply the requested information within the next 30 days. While the company is optimistic about its ability to perform the studies requested, until the requested studies are re-run, the Company is unable to assess what the probable response of the FDA will be to the new documentation, and no assurances can be given that the Company will ever receive FDA clearance for the commercial sale of DR-70 ® in the United States.”

The following link refers to a transcript, dated 5/21/2008. Does the schpeel sound familiar?
http://google.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHtmlSection1?SectionID=5957594-6105-39958&SessionID=6aioHC33MvwLrG7

Below is a VISUAL of all this BS from 2005+.
Left-hand chart is for AMDL - ticker: ADL
Right-hand chart is RPC
Notice any repeating patterns??



2009: AMDL rebranded their company with new name Radient Pharmaceuticals:
http://www.advfn.com/news_AMDL-Inc-Announces-Stockholder-Approval-of-Name-Change-and-Issuance-of-a-New-Tr_39532196.html

seriously, year after year, after year...???

QUESTION: What on earth has AMDL (ADL), aka, RPC really accomplished over the years besides desperately trying to market Onko-Sure (D-70) and pumping CIT???

IMO - All of the new news is nothing more than VERY OLD NEWS.